홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

4-Methylmorpholine → (R/S)-2-hydroxy-N-(2-(1-methylazetidin-3-ylamino)-2-oxoethyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide

HRID 77156
인쇄

반응식

HRID 77156 반응식
[OH:1][CH:2]([C:10]1[CH:15]=[CH:14][C:13]([C:16]2[N:20]=[C:19]([C:21]3[O:25][N:24]=[C:23]([C:26]4[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=4)[C:22]=3[C:32]([F:35])([F:34])[F:33])[O:18][N:17]=2)=[CH:12][CH:11]=1)[C:3]([NH:5][CH2:6][C:7](O)=[O:8])=[O:4].CN1CCOCC1.Cl.Cl.[CH3:45][N:46]1[CH2:49][CH:48]([NH2:50])[CH2:47]1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>CN(C=O)C>[OH:1][CH:2]([C:10]1[CH:15]=[CH:14][C:13]([C:16]2[N:20]=[C:19]([C:21]3[O:25][N:24]=[C:23]([C:26]4[CH:27]=[CH:28][CH:29]=[CH:30][CH:31]=4)[C:22]=3[C:32]([F:35])([F:34])[F:33])[O:18][N:17]=2)=[CH:12][CH:11]=1)[C:3]([NH:5][CH2:6][C:7]([NH:50][CH:48]1[CH2:49][N:46]([CH3:45])[CH2:47]1)=[O:8])=[O:4]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 4

HCID 79724-MethylmorpholineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 447849011-Methylazetidin-3-amine dihydrochlorideHCID 674575572-(2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamido)acetic acid

생성물 1

HCID 53497283
(R/S)-2-hydroxy-N-(2-(1-methylazetidin-3-ylamino)-2-oxoethyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide
수율 32.8%

시약·촉매·용매 1

HCID 6228Dimethylformamide용매

실험 절차

(R/S)-2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid (Int-V, 160 mg, 0.371 mmol) was dissolved in DMF (1 mL) prior to the addition of 4-methylmorpholine (0.245 mL, 2.226 mmol), tert-butyl 2-aminoacetate (88 mg, 0.668 mmol), and HATU (254 mg, 0.668 mmol). The reaction mixture was stirred overnight before EtOAc was added. The EtOAc solution was washed with 1N HCl, sat NaHCO3, and brine. The organic layer was then dried (MgSO4) and concentrated to give (R/S)-tert-butyl 2-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamido)acetate (159.5 mg, 0.293 mmol): LCMS=546.2 [M+H]+. The (R/S)-tert-butyl 2-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamido)acetate (159 mg, 0.294 mmol) was dissolved in CH2Cl2 (1 mL) and TFA (2.0 mL). This was stirred for 1 h and was then concentrated to give 2-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamido)acetic acid (148 mg, 0.303 mmol): LCMS=489.1 [M+H]+. A portion of the (R/S)-2-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamido)acetic acid (30 mg, 0.061 mmol) was dissolved in DMF (1 mL) prior to the addition of 4-methylmorpholine (0.041 mL, 0.369 mmol), 1-methylazetidin-3-amine-2HCl (17.59 mg, 0.111 mmol), and HATU (42.0 mg, 0.111 mmol). This was stirred overnight and was then purified via preparative LCMS with the following conditions: Column: Waters XBridge C18, 19×250 mm, 5-μm particles; Guard Column: Waters XBridge C18, 19×10 mm, 5-μm particles; Mobile Phase A: 5:95 methanol:water with 10-mM ammonium acetate; Mobile Phase B: 95:5 methanol:water with 10-mM ammonium acetate; Gradient: 50-100% B over 25 minutes, then a 5-minute hold at 100% B; Flow rate=20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to give (R/S)-2-hydroxy-N-(2-(1-methylazetidin-3-ylamino)-2-oxoethyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide (11.3 mg, 0.020 mmol, 32.4% yield): LCMS=557.2 [M+H]+; 1H NMR (400 MHz, methanol-d4) δ ppm 8.18 (2 H, d, J=8.28 Hz), 7.66-7.80 (4 H, m), 7.55-7.65 (3 H, m), 5.20 (1 H, s), 4.47 (1 H, t, J=7.28 Hz), 3.82-4.02 (4 H, m), 3.49 (2 H, t, J=7.78 Hz), 2.58 (3 H, s); Analytical LCMS: column: Mac-mod Halo C18, 4.6×50 mm, 2.7-μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 90:10 acetonitrile:water with 10 mM ammonium acetate; Temperature: 45° C.; Gradient: 0-100% B over 4 minutes, flow rate=4 mL/min, product retention=2.1 min.

후처리

  1. customwas then purified via preparative LCMS with the following conditions
  2. waitGradient: 50-100% B over 25 minutes
  3. customa 5-minute hold
  4. additionFractions containing the desired product
  5. customdried via centrifugal evaporation

출처 및 근거

ORD 기록
ord-679d6519bf1a4b55b2d9a4dbd5aeea64
출처 데이터셋
uspto-grants-2014_09
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08835470B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트